Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
CGTX Cognition Therapeutics
2.120+0.200+10.42%
Close
02/03 16:00 ET
2.100-0.020-0.94%
Post Mkt Price 02/03 19:59 ET
High
2.140
Open
1.989
Turnover
480.53K
Low
1.840
Pre Close
1.920
Volume
240.57K
Post-Market
5D
1D
1W
1M
1Q
1Y
Price Forecast
News
Comment
Cognition Therapeutics Has Received A Notice Of Allowance For Its U.S. Patent Application 16/783,943 Titled "Isoindoline Compositions And Methods For Treating Neurodegenerative Disease (Including Alzheimer's Disease)".
Cognition Therapeutics Has Received A Notice Of Allowance For Its U.S. Patent Application 16/783,943 Titled "Isoindoline Compositions And Methods For Treating Neurodegenerative Disease (Including Alzh
Cognition Therapeutics, Inc. (NASDAQ:CGTX) Sees Large Decrease in Short Interest
Cognition Therapeutics, Inc. (NASDAQ:CGTX – Get Rating) was the recipient of a significant decrease in short interest during the month of December. As of December 30th, there was short interest total
Analyzing Agenus (NASDAQ:AGEN) and Cognition Therapeutics (NASDAQ:CGTX)
Agenus (NASDAQ:AGEN – Get Rating) and Cognition Therapeutics (NASDAQ:CGTX – Get Rating) are both small-cap medical companies, but which is the superior business? We will compare the two companies bas
Head-To-Head Survey: Agenus (NASDAQ:AGEN) & Cognition Therapeutics (NASDAQ:CGTX)
Agenus (NASDAQ:AGEN – Get Rating) and Cognition Therapeutics (NASDAQ:CGTX – Get Rating) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses b
Short Interest in Cognition Therapeutics, Inc. (NASDAQ:CGTX) Declines By 49.3%
Cognition Therapeutics, Inc. (NASDAQ:CGTX – Get Rating) was the target of a large decrease in short interest in the month of December. As of December 15th, there was short interest totalling 160,600
Cognition Therapeutics Files For Mixed Shelf Of Up To $200M
Cognition Therapeutics Files For Mixed Shelf Of Up To $200M
Cognition Therapeutics Announces New “Conversations” Podcast Episode on Key Insights From Recent Clinical Trials in Alzheimer’s Disease
- Features Alzheimer's Experts: Christopher van Dyck, M.D. and Anton Porsteinsson, M.D. - PURCHASE, N.Y., Dec. 22, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (Nasdaq: CGTX), (the "Compan
First Participant Dosed in Europe as Cognition Therapeutics Expand Phase 2 Alzheimer's Disease Clinical Trial of Oral CT1812
SHINE Study Expanded from USA to Include sites in Spain, the Netherlands, and Czech RepublicPURCHASE, N.Y., Dec. 15, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX) (the "Compan
Cognition Therapeutics Shares Halted On Circuit Breaker To The Downside, Stock Now Down 13.1%
Cognition Therapeutics Shares Halted On Circuit Breaker To The Downside, Stock Now Down 13.1%
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
GainersPrometheus Biosciences (NASDAQ:RXDX) stock rose 182.9% to $102.0 during Wednesday's pre-market session. The company's market cap stands at $4.2 billion. TransCode Therapeutics (NASDAQ:RNAZ) sto
Company Overview
More
Cognition Therapeutics, Inc. is a clinical stage neuroscience company. The firm develops drugs that help restore normal cellular damage responses in neurodegenerative and neuro-ophthalmic disorders. The company was founded by Franz F. Hefti, Gilbert M. Rishton, and Susan M. Catalano in 2007 and is headquartered in Purchase, NY.
CEO： Ms. Lisa Ricciardi
Market： NASDAQ
Listing Date： 10/08/2021
Paper Trade
More
Hot List
TradeSearchNews
SymbolLatest price%Chg
Loading...
Watchlist
No Stock Yet